Business Wire

OR-AIRSHIP

23.9.2021 15:02:05 CEST | Business Wire | Press release

Share
New Airship Preference Center Gives Marketers Full Control to Retain Consumer Opt-ins Without Ongoing Developer Support Ahead of Changes to iOS 15 Notifications

Apple’s newly introduced iOS 15 gives consumers greater control over how, when and where notifications arrive on their phone. If these new features are broadly adopted, current practices for notifications may not light up smartphone screens to immediately alert users. Since most iPhones will soon be running on iOS 15, it’s imperative that brands optimize their mobile engagement strategies to better serve their valuable app audiences with individualized preferences and exceptional, real-time experiences.

In order to accelerate brands’ efforts, customer engagement company Airship today announced the availability of Airship Preference Center — the industry’s first marketer-friendly preference center that makes it simple to create, manage and optimize customers’ opt-in choices without ongoing developer support or requisite app updates for the App Store or Google Play.

In addition to Airship Preference Center, the company’s day-one support for iOS 15 allows marketers to specify interruption levels for notifications — Passive, Active, Time Sensitive, or Critical — which iOS 15 uses to determine how they will be delivered. For example, a notification can be set to break through a ‘Focus’ mode to immediately alert a user, or it can be selected to arrive with an audible alert or not. Marketers can also use Airship to set relevance scores for notifications and to add rich media, which alongside user behavior, sets the order and prominence of a brand’s messages within the user-scheduled Notifications Summary.

“Mobile apps have been a lifeline for both businesses and consumers throughout the pandemic, offering faster purchasing, richer content and streamlined conveniences like curbside pickup. However, new user-centric notification controls mean marketers must be much clearer and more precise in the preference choices offered to customers to ensure the communications they receive are relevant and valued,” said Brett Caine, CEO and president, Airship. “Airship Preference Center brings unparalleled speed and flexibility to understand individual customer preferences, and fine-tune the experience with the full power of our platform to reach people when and where it matters most to them.”

Airship Preference Center is seamlessly integrated within Airship’s SaaS Customer Engagement Platform, enabling marketers to easily guide customers to their preference center through contextually triggered in-app messages or any number of cross-channel journeys for onboarding, loyalty enrollment, new subscription content and more. Airship’s easy-to-use composer enables marketers to quickly create multiple subscription lists spanning popular interests, topics or types of messages without the need for developer support.

For example, marketing messages like sales events and flash deals, or transactional messages like monthly statements or delivery/curbside pickup alerts, provide a range of urgency and convenience that expands consumer choice and improves long term opt-in retention as customers get what they want on each mobile channel. Marketers can automate combining opt-in selections with customers’ real-time mobile behaviors for hyper-personalized messaging. It’s also easy to track list opt-ins or review in-depth Performance Analytics reports to continually fine-tune and enhance options offered to customers.

“As pandemic restrictions lift and broad-scale travel resumes it’s absolutely vital that we connect our customers to the best values and broader inspiration to satisfy pent-up wanderlust,” said Dave McCormick, Managing Director - Product & Design, Alaska Airlines. “Airship’s Preference Center will provide an easy and efficient way to ensure marketing messages do not diminish the role our mobile app plays as a real-time travel companion, notifying customers of when they can check-in or if there happens to be a gate change.”

Register for Elevate 2021 , a virtual global forum for marketers and mobile product owners, taking place October 27-28, 2021. Attendees will learn about mobile-first best practices and insights driving innovation, business growth and deeper customer connections for dozens of leading brands around the world.

Airship in Independent Industry Analyst Evaluations

Airship was recently named a Leader in “The Forrester Wave™: Mobile Engagement Automation, Q3 2020 ,” receiving the highest score in the Strategy category and the second highest score in the Current Offering category.

Also, for the second consecutive year, Airship was positioned highest in its ability to execute and also furthest for its completeness of vision in Gartner’s 2020 Magic Quadrant for Mobile Marketing Platforms 1 , and received the highest Product Scores across all three Use Cases in Gartner’s 2020 Critical Capabilities for Mobile Marketing Platforms 2 , including the Acquisition, Engagement and Retention Use Cases.

1 Gartner “Magic Quadrant for Mobile Marketing Platforms ” by Mike McGuire, Anna Maria Virzi, Joseph Enever, October 26, 2020

2 Gartner “Critical Capabilities for Mobile Marketing Platforms ” by Mike McGuire, Anna Maria Virzi, Joseph Enever, October 29, 2020

Gartner Disclosure

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Airship

Thousands of the world’s leading brands rely on Airship to spark exceptional experiences with their customers through highly contextual and relevant interactions. Only Airship’s SaaS Customer Engagement Platform takes a mobile-first, data-led approach that enables brands to focus on individuals and their needs, rather than which marketing channels to use. Airship makes it much simpler and more effective to grow customer lifetime value in the omnichannel era.

With trillions of interactions intelligently orchestrated across mobile apps, mobile wallet, SMS, websites, and email, Airship optimizes the entire customer journey across all digital touchpoints at scale.

For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .

Link:

ClickThru

Social Media:

https://www.facebook.com/airshipsocial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye